This webinar series includes the presentations and the audience QAs recorded from the live broadcast and the associated slide handouts. If you would like continuing education credit for the webinars, click on the links in the table below to access the webinars + CME/CMLE or webinars + SAM
Neal Lindeman, MD
Eric H. Bernicker, MD
Dara Aisner, MD, PhD
Lynette M. Sholl, MD
Sinchita Roy-Chowdhuri, MD, PhD
Christopher R. Gilbert, DO, MS, FCCP
Series Description: Over the past 10 years, understanding of oncogenic signal transduction pathways has fundamentally altered the treatment paradigm for advanced NSCLC, leading to personalized treatment. As a result, diagnosing and treating NSCLC has evolved from a relatively simple “one-size-fits-all” approach to an extremely complex algorithm that requires personalized treatment plans.
This free online learning experience is aimed at breaking down barriers to testing and treatment in Non-Small Cell Lung Cancer (NSCLC). Hear from world-renowned experts and explore best practices in test ordering, sample collection, and test interpretation with the goal of improving patient care.
Webinars include: (Click "Topic" tab for descriptions)
Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
Speaker: Neal Lindeman
Recorded: May 29, 2018
Best Practices in NSCLC Small Specimen Collection for Clinicians
Speaker: Eric Bernicker
Recorded: June 20, 2018
Best Practices in Small Specimen Management for Laboratory Professionals
Speaker: Dara Aisner
Recorded: August 16, 2018
Liquid Biopsies – Promises and Pitfalls
Recorded: October 9, 2018
Best Practices in Test Ordering
Speakers: Sinchita Roy-Chowdhuri and Christopher R. Gilbert
Recorded: December 13, 2018
Duration: 5 hr
Level of Instruction: Basic
Add the entire series into your classroom by clicking "Add to Basket" button located on the right.
Add individual webinars into your classroom by clicking on the "Purchase Individual Topics" button on the right. Select the particular webinar(s) that you would like and proceed through checkout.
This webinar is a five-part series aimed at breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here.
Supported by an educational grant provided by AstraZeneca
Click on the links below to access continuing education credit.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
May 29, 2018
Explain how targeted therapies are selected for patients with advanced adenocarcinoma of the lung.
Evaluate how the evidence published since the original 2013 guideline have been impacted by new observations and evidence since the first guideline.
Explain how molecular pathologists would utilize the recommendations in clinical practice using a case-based learning approach.
Discuss the need for repeat biopsies upon progression so that therapies that target mechanisms of acquired resistance can be appropriately utilized.
Identify key obstacles to ensuring adequate tissue availability for molecular analysis in new diagnosis samples of NSCLC.
Review the new recommendations for lung cancer biomarker testing, their impact on patient care, and appropriate methods of testing (pre-analytic, analytic and post analytic actions).
Identify factors that may lead to discrepant results when comparing tumor genomic alterations across platforms or biopsy types.
Discuss approaches for optimal tissue processing to maximize chances of ensuring successful molecular testing in NSCLC specimens.
Identify key obstacles to ensuring adequate specimen collection for molecular analysis in NSCLC patients.
Elaborate on technical approaches to the specimen handling and laboratory processes which can maximize tissue preservation for molecular testing while maintaining diagnostic integrity.
Recognize the biological and technical challenges that limit the sensitivity of liquid biopsy.